CoChat
Sign Up
Cited by 177Lipoproteins and Cardiovascular HealthNitric Oxide and Endothelin EffectsCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function

Open access
Wassmann, Sven, Faul, Anna, Hennen, Benno, Scheller, Bruno, Böhm, Michael, Nickenig, Georg·2003·Circulation Research
DOI 10.1161/01.res.0000099503.13312.7b
Open this paper in CoChat — free accountOpen PDF

Abstract

Treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) decreases cardiovascular event rates in hypercholesterolemic patients. Whether statins exert effects within 24 hours on the coronary vasculature in patients with endothelial dysfunction has not been elucidated. Twenty-seven patients with stable angina pectoris and average low-density lipoprotein cholesterol concentrations of 138±9 mg/dL at baseline were allocated to treatment with placebo (14 patients) or 40 mg/d pravastatin (13 patients) in a randomized, double-blind, prospective trial. Coronary endothelial function was assessed before and 24 hours after single treatment by quantitative coronary angiography during intracoronary infusion of nitroglycerin or increasing concentrations of acetylcholine (0.01, 0.1, and 1 μmol/L). Coronary blood flow reserve was measured by Doppler velocimetry during adenosine infusion. Intracoronary acetylcholine infusion induced abnormal vasoconstriction in both groups before treatment, indicating coronary endothelial dysfunction. Treatment with a single oral 40-mg dose of pravastatin significantly attenuated acetylcholine-mediated vasoconstriction after 24 hours (mean±SE decrease in luminal diameter before and after treatment: 0.01 μmol/L, 6.1±2.2% versus 3.0±1.2%; 0.1 μmol/L, 15.6±2.6% versus 7.4±1.8%; P <0.05; 1 μmol/L, 22.9±2.9% versus 13.2±2.6%; P <0.05). There was no significant difference in the response to acetylcholine in the placebo group (8.1±2.4% versus 9.7±2.4%, 16.1±2.9% versus 16.8±3.2%, and 21.4±3.9% versus 23.3±4.2%). The response to nitroglycerin infusion was not altered in both groups. Increase in coronary blood flow in response to adenosine and coronary flow reserve remained unchanged during placebo and statin treatment. Serum concentrations of blood lipids and high-sensitive C-reactive protein were not significantly altered after 24 hours in response to placebo or pravastatin therapy. Statin treatment improves endothelium-dependent coronary vasomotion within 24 hours in the absence of significant cholesterol reduction. The full text of this article is available online at http://www.circresaha.org.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.res.0000099503.13312.7b

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 14

  1. 10.1161/atvb.21.11.1712 · DOI
  2. 10.1161/circ.89.6.8205659 · DOI
  3. 10.1161/circ.101.16.1899 · DOI
  4. 10.1161/circ.101.9.948 · DOI
  5. 10.1161/circ.104.22.2673 · DOI
  6. 10.1161/circ.104.4.376 · DOI
  7. 10.1161/circ.95.5.1126 · DOI
  8. 10.1161/circ.97.12.1129 · DOI
  9. 10.1161/circ.105.8.933 · DOI
  10. 10.1161/atvb.22.2.300 · DOI
  11. 10.1161/atvb.20.1.61 · DOI
  12. 10.1161/atvb.21.1.122 · DOI
  13. 10.1161/circ.95.1.76 · DOI
  14. 10.1161/circ.100.3.230 · DOI

Cited by

Sorted by citations

See all 177

Related

See all

Metadata

Authors
Wassmann, S., Faul, A., Hennen, B., Scheller, B., Böhm, M., & Nickenig, G.
Affiliations
  • Universitätsklinikum des Saarlandes (DE)
  • From Medizinische Klinik und Poliklinik, Innere Medizin III, Universitätskliniken des Saarlandes, Homburg/Saar, Germany.
ORCID
Venue
Circulation Research
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2003-10-31
Volume
93
Issue
9
Pages
e98-103
ISSN
  • 0009-7330 (ISSN-L)
  • 1524-4571
DOI
10.1161/01.res.0000099503.13312.7b
OpenAlex
W2166462038
Cited by
177
References
41
Citations by year
2026: 2 · 2025: 2 · 2023: 5 · 2022: 1 · 2021: 6 · 2020: 3 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 8 · 2014: 8 · 2013: 5 · 2012: 11
FWCI
16.72
Type
journal article
Language
en
Open access
Locations
  • Circulation Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Deutsche Forschungsgemeinschaft
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords
pravastatin, statins, coronary endothelial function, endothelial dysfunction, acetylcholine-induced vasoconstriction, nitroglycerin, coronary blood flow reserve, adenosine, stable angina, hypercholesterolemia, coronary vasculature, lipid-lowering therapy
MeSH terms
Aged, Angina Pectoris, Blood Flow Velocity, Blood Pressure, C-Reactive Protein, Coronary Circulation, Coronary Vessels, Double-Blind Method, Endothelium, Vascular, Female, Heart Rate, Humans, Hydroxymethylglutaryl CoA Reductases, Lipids, Male, Middle Aged, Prospective Studies, Time Factors, Vascular Patency, Vasodilation, Vasodilator Agents, Coronary Angiography, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review